S Hassan1, S J Seung1, M C Cheung2, G Fraser3, B Kuriakose4, C Trambitas4, N Mittmann5. 1. Health Outcomes and PharmacoEconomics ( hope ) Research Centre, Sunnybrook Research Institute, Toronto. 2. Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto;; Department of Medicine, Division of Hematology, University of Toronto, Toronto. 3. Juravinski Cancer Centre, Hamilton Health Sciences Centre, Hamilton;; Department of Oncology, Division of Malignant Hematology, McMaster University, Hamilton. 4. Janssen Inc., Toronto; and. 5. Health Outcomes and PharmacoEconomics (hope) Research Centre, Sunnybrook Research Institute, Toronto;; Department of Pharmacology, University of Toronto, Toronto, ON.
Abstract
PURPOSE: The purpose of the present study was to collect medical resource utilization data and costs in Ontario for the management of patients with relapsed or refractory chronic lymphocytic lymphoma (cll) who have undergone at least 1 treatment course and have been stratified by Rai staging. METHODS: This retrospective longitudinal cohort study, conducted by chart review, analyzed anonymized patient records from two cancer centres in Ontario. Comprehensive records of 86 patients meeting the inclusion criteria were used to obtain resource utilization, which, multiplied by unit costs, were used to determine overall and mean costs. Descriptive statistics are presented for patient demographics, medical resource utilization, and costing data. RESULTS: The total cost for the cohort was $2.2 million over a mean follow-up period of 4.7 years. The mean total cost per patient (regardless of follow-up) was $25,736. In terms of Rai staging, overall mean costs were highest for stage iv patients. Almost 50% of the total cost was attributable to cll treatments, among which fludarabine-based treatments had the highest utilization. CONCLUSIONS: For this Canadian cll cohort, medical resource utilization and costs were determined to be $2.2 million, with cll treatments accounting for about half the cost. Costs generally increased with Rai stage.
PURPOSE: The purpose of the present study was to collect medical resource utilization data and costs in Ontario for the management of patients with relapsed or refractory chronic lymphocytic lymphoma (cll) who have undergone at least 1 treatment course and have been stratified by Rai staging. METHODS: This retrospective longitudinal cohort study, conducted by chart review, analyzed anonymized patient records from two cancer centres in Ontario. Comprehensive records of 86 patients meeting the inclusion criteria were used to obtain resource utilization, which, multiplied by unit costs, were used to determine overall and mean costs. Descriptive statistics are presented for patient demographics, medical resource utilization, and costing data. RESULTS: The total cost for the cohort was $2.2 million over a mean follow-up period of 4.7 years. The mean total cost per patient (regardless of follow-up) was $25,736. In terms of Rai staging, overall mean costs were highest for stage iv patients. Almost 50% of the total cost was attributable to cll treatments, among which fludarabine-based treatments had the highest utilization. CONCLUSIONS: For this Canadian cll cohort, medical resource utilization and costs were determined to be $2.2 million, with cll treatments accounting for about half the cost. Costs generally increased with Rai stage.
Authors: M Hallek; K Fischer; G Fingerle-Rowson; A M Fink; R Busch; J Mayer; M Hensel; G Hopfinger; G Hess; U von Grünhagen; M Bergmann; J Catalano; P L Zinzani; F Caligaris-Cappio; J F Seymour; A Berrebi; U Jäger; B Cazin; M Trneny; A Westermann; C M Wendtner; B F Eichhorst; P Staib; A Bühler; D Winkler; T Zenz; S Böttcher; M Ritgen; M Mendila; M Kneba; H Döhner; S Stilgenbauer Journal: Lancet Date: 2010-10-02 Impact factor: 79.321
Authors: Tadeusz Robak; Anna Dmoszynska; Philippe Solal-Céligny; Krzysztof Warzocha; Javier Loscertales; John Catalano; Boris V Afanasiev; Loree Larratt; Christian H Geisler; Marco Montillo; Ilya Zyuzgin; Peter S Ganly; Caroline Dartigeas; András Rosta; Jörg Maurer; Myriam Mendila; M Wayne Saville; Nancy Valente; Michael K Wenger; Sergey I Moiseev Journal: J Clin Oncol Date: 2010-03-01 Impact factor: 44.544
Authors: Barbara F Eichhorst; Raymonde Busch; Stephan Stilgenbauer; Martina Stauch; Manuela A Bergmann; Matthias Ritgen; Nicole Kranzhöfer; Robert Rohrberg; Ulrike Söling; Oswald Burkhard; Anne Westermann; Valentin Goede; Carmen D Schweighofer; Kirsten Fischer; Anna-Maria Fink; Clemens M Wendtner; Günter Brittinger; Hartmut Döhner; Bertold Emmerich; Michael Hallek Journal: Blood Date: 2009-07-15 Impact factor: 22.113
Authors: M D Seftel; A A Demers; V Banerji; S B Gibson; C Morales; G Musto; M W Pitz; J B Johnston Journal: Leuk Res Date: 2009-07-05 Impact factor: 3.156